Advertisement

Topics

Latest "FluGen Inc." News Stories

22:10 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "FluGen Inc." found in our extensive news archives from over 250 global news sources.

More Information about FluGen Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about FluGen Inc. for you to read. Along with our medical data and news we also list FluGen Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of FluGen Inc. Companies for you to search.

Showing "FluGen" News Articles, all 9

Friday 22nd February 2019

FluGen success brings the reality of universal influenza vaccines closer

On 12 February, FluGen announced preliminary results from a successful Phase II trial of its investigational nasal influenza vaccine M2SR...Read More... The post FluGen success brings the reality of universal influenza vaccines closer appeared first on Pharmaceutical Technology.


Friday 15th February 2019

WI Watchlist: FluGen, Propeller Health, Gener8tor, EnSync

Here are some of the latest headlines from Wisconsin’s innovation community: —FluGen, a Madison-based company trying to develop a universal influenza vaccine, announced topline, preliminary data from a Phase 2 study that demonstrated its M2SR vaccine proved effective in countering a “mismatched” flu virus. The flu virus that makes its rounds each year doesn’t always [...

Tuesday 12th February 2019

FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus

— Topline data shows first flu vaccine to demonstrate protection against a multi-season mismatched H3N2 strain in a human challenge clinical trial — — Intranasal administration of M2SR well-tolerated in trial — — Protection against influenza challenge correlated with serum response to M2SR — — Important step ...


Wednesday 19th December 2018

FluGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryFluGen Inc FluGen is a developer of influenza vaccines and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product include redeeflu, a nasal spray vaccine used to protect against influenza that contains mutations in the M2 gene of the virus. FluGen's redeeflu provides better efficacy against seasonal and...

Monday 19th November 2018

WI Watchlist: Gener8tor, FluGen, Sift Healthcare, Titan Spine

Before everyone tucks into turkey later this week, let’s catch up on some recent headlines from Wisconsin’s high-tech sectors: —Wisconsin-based Gener8tor, which runs a network of programs that train and invest in startups, continues to expand. Its latest offering is the OnRamp Insurance Accelerator, an insurance technology-focused program that will be located in the Minneapolis [...

Monday 15th October 2018

FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains

—Influenza challenge virus genetically drifted by six years from vaccine strain— FluGen, Inc. announced today that all subjects have completed dosing in a first-of-its-kind clinical study which challenged subjects with an influenza virus that was intentionally mismatched by six years from the influenza strain utilized in FluGen’s M2SR vaccine. ...

Thursday 4th October 2018

FluGen Presents First-in-Human Phase 1a Safety and Immunogenicity Data with Novel M2SR Influenza Vaccine at ID Week

—Vaccine safe and well tolerated at all dose levels in trial— —Significant humoral, mucosal and T-cell responses produced by vaccine— —Goal of drifted/multi-season protection under evaluation in new, ongoing Phase 2 trial— FluGen, Inc. announced today that the company’s novel M2 deleted, single replication (M2SR) ...

Wednesday 19th September 2018

NIH Using Vaccines from Madison Startup FluGen in New Clinical Trial

Researchers are testing a flu vaccine developed by FluGen, a Madison, WI-based startup, to determine whether it can protect recipients against strains of the virus that vary from the predominant strain flu predicted by health experts each year. Many people get a flu shot this time of year in hopes that it will help them […]

Thursday 9th August 2018

FluGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11072018] Prices from USD $250

SummaryFluGen Inc FluGen is a developer of influenza vaccines and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product include redeeflu, a nasal spray vaccine used to protect against influenza that contains mutations in the M2 gene of the virus. FluGen's redeeflu provides better efficacy against seasonal and...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks